Mar 22, 2017
Preclinical Proof-of-Concept Achieved, IND-Enabling Activities Underway Cambridge, MA, March 22, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of...
Nov 9, 2016
Industry Veterans Bring Deep Industry Experience to Support Future Growth Cambridge, MA, November 9, 2016 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases and cancer, today announced the...
Aug 2, 2016
Company Leverages Disruptive Therapies to Create New Paradigms in the Treatment of Fabry Disease and Acute Myeloid Leukemia Cambridge, MA, August 2, 2016 – AVROBIO, Inc, a clinical-stage biotechnology company developing transformative, life-changing gene therapies for...
May 13, 2016
May 13, 2016 Cambridge, MA May 13, 2016 – AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, today announced it has been awarded lab space at Johnson & Johnson’s (J&J)...
Feb 18, 2016
Disruptive Therapies with Potential to Displace Standard of Care Treatments for Acute Myeloid Leukemia (AML) and Fabry Disease Announces Management Team of Industry Leaders with Unmatched Scientific, Business and Manufacturing Expertise in Cell and Gene Therapies and...
